Cure8 research brief
People with IBD and those on commonly used biologics may have different early T cell responses and faster waning after SARS-CoV-2 vaccination, which could affect timing or interpretation of immune monitoring and booster planning.
Adult IBD patients (especially those on anti-TNF or anti-IL-12/23 therapy), clinicians managing IBD and vaccine timing, and researchers studying vaccine immunity in immunosuppressed populations.
The researchers looked specifically at IBD patients to reduce heterogeneity seen in prior IMID studies. After one vaccine dose, IBD patients showed fewer Th1-polarized spike-reactive T cells and more Th2 cells versus healthy controls. There was also increased waning of spike-specific cytokine responses after two doses.
Patients treated with anti-TNF or anti-IL-12/IL-23 biologics had lower spike-specific IL-2 secretion than untreated IBD patients following one dose.
However, single-cell RNA sequencing of spike-responsive T cells collected 2–4 weeks after two or three doses found no major differences in T cell subset composition, transcriptomes, or TCR diversity between treated patients and healthy controls.
Bottom line: the paper suggests some impairment in early or waning T cell responses in IBD patients — and some treatment-related effects after a single dose — but after a full vaccine course spike-reactive T cells in biologic-treated patients appeared similar to healthy controls.
Structured content depth: abstract — the supplied text is an abstract from the journal article. This brief is grounded in that abstract and does not reflect review of the full manuscript. Results describe immune response measurements; they are not clinical recommendations.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Canada Research Chair in Anti-viral Immunity, University of Toronto; University of Toronto; CIHR Canada Graduate Scholarships Doctoral - FBD-187492; Canadian Institutes of Health Research (CIHR)/COVID-Immunity Task Force (CITF) - GA2-177716; Psoriatic Arthritis Research at UHN
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
People with IBD (including those on TNF inhibitors) may benefit from research that explains why some patients don’t respond to anti-TNF drugs and that points to new biologic targets. Understanding cell types and...
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...
